Salbutamol as needed
Sponsors
GlaxoSmithKline
Conditions
Pulmonary Disease, Chronic Obstructive
Phase 3
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01323621
Start: 2011-03-18End: 2012-01-24Updated: 2018-02-15
A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01706328
Start: 2012-10-15End: 2013-06-17Updated: 2018-05-02